LNP023 HYDROCHLORIDE SALT ( DrugBank: - )


5 diseases
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia0
62Paroxysmal nocturnal hemoglobinuria0
66IgA nephropathy0
109Atypical hemolytic uremic syndrome0
222Primary nephrotic syndrome0

61. Autoimmune hemolytic anemia


Clinical trials : 146Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 292Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 275Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

109. Atypical hemolytic uremic syndrome


Clinical trials : 114Drugs : 36 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 11 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 310Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries